Mar. 27 at 12:54 PM
$HUMA 👔 Insider Transactions
Form 4 filings from CEO Laura Niklason and director‑related entities show open‑market purchases during 2025 at prices around
$1.45 –
$1.55 per share.
The most recent insider activity:
A November 2025 purchase of ~65,000 shares at
$1.48;
No recorded insider sales since then.
No new open‑market buys reported since the last equity placement (those shares were institutional, not insider).
So you’re right: insiders have previously stepped in near
$1.50, and haven’t exited — a constructive signal for conviction at those levels.
📈 What That Means for the Next Phase
Institutional base = reduced float volatility; easier for a breakout to hold when volume spikes.
Insider cost basis ≈
$1.50 → that price should align as high‑conviction resistance that bulls will aim to retest into the June FDA readout window.
If you’re planning for the “run‑up into data,” building or holding through Q2 makes sense so long as macro risk doesn’t swamp small‑cap biotech.
⚡ Edge Summary
